share_log

Shanghai Chicmax Cosmetic Co., Ltd. Just Beat EPS By 6.8%: Here's What Analysts Think Will Happen Next

Shanghai Chicmax Cosmetic Co., Ltd. Just Beat EPS By 6.8%: Here's What Analysts Think Will Happen Next

上海Chicmax化妆品有限公司刚刚超过每股收益6.8%:以下是分析师认为接下来会发生的事情
Simply Wall St ·  03/23 21:14

As you might know, Shanghai Chicmax Cosmetic Co., Ltd. (HKG:2145) just kicked off its latest full-year results with some very strong numbers. Results were good overall, with revenues beating analyst predictions by 3.3% to hit CN¥4.2b. Statutory earnings per share (EPS) came in at CN¥1.16, some 6.8% above whatthe analysts had expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

你可能知道,上海Chicmax化妆品有限公司(HKG: 2145)刚刚以一些非常强劲的数字拉开了其最新的全年业绩。总体业绩良好,收入比分析师的预期高出3.3%,达到42亿元人民币。法定每股收益(EPS)为1.16元人民币,比分析师的预期高出约6.8%。对于投资者来说,盈利是一个重要时刻,因为他们可以追踪公司的业绩,查看分析师对明年的预测,看看对公司的情绪是否发生了变化。因此,我们收集了最新的财报后预测,以了解估计对明年的预测。

earnings-and-revenue-growth
SEHK:2145 Earnings and Revenue Growth March 24th 2024
SEHK: 2145 2024年3月24日收益和收入增长

After the latest results, the six analysts covering Shanghai Chicmax Cosmetic are now predicting revenues of CN¥6.94b in 2024. If met, this would reflect a huge 66% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to leap 65% to CN¥1.91. Before this earnings report, the analysts had been forecasting revenues of CN¥5.62b and earnings per share (EPS) of CN¥1.57 in 2024. There has definitely been an improvement in perception after these results, with the analysts noticeably increasing both their earnings and revenue estimates.

最新业绩公布后,报道上海Chicmax化妆品的六位分析师现在预测2024年的收入为69.4亿元人民币。如果得到满足,这将反映出收入与过去12个月相比大幅增长了66%。预计每股法定收益将增长65%,至1.91元人民币。在本财报发布之前,分析师一直预测2024年的收入为56.2亿元人民币,每股收益(EPS)为1.57元人民币。这些业绩公布后,人们的看法肯定有所改善,分析师的收益和收入预期均明显上升。

With these upgrades, we're not surprised to see that the analysts have lifted their price target 17% to HK$52.51per share. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Shanghai Chicmax Cosmetic analyst has a price target of HK$59.73 per share, while the most pessimistic values it at HK$46.78. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

通过这些上调,分析师将目标股价上调了17%,至每股52.51港元,我们并不感到惊讶。但是,固定单一价格目标可能是不明智的,因为共识目标实际上是分析师目标股价的平均值。因此,一些投资者喜欢查看估计范围,看看对公司的估值是否有任何分歧。最乐观的上海Chicmax化妆品分析师将目标股价定为每股59.73港元,而最悲观的估值为46.78港元。尽管如此,由于估计范围如此之窄,这表明分析师对他们认为该公司的价值有了很好的了解。

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Shanghai Chicmax Cosmetic's growth to accelerate, with the forecast 66% annualised growth to the end of 2024 ranking favourably alongside historical growth of 2.0% per annum over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 8.9% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Shanghai Chicmax Cosmetic is expected to grow much faster than its industry.

我们可以从大局的角度看待这些估计值的另一种方式,例如预测如何与过去的表现相提并论,以及预测相对于业内其他公司是否或多或少看涨。分析师肯定预计上海Chicmax化妆品的增长将加速,预计到2024年底的年化增长率为66%,而过去三年的历史年增长率为2.0%。相比之下,我们的数据表明,预计类似行业的其他公司(有分析师报道)的收入将以每年8.9%的速度增长。考虑到收入增长的预测,很明显,上海Chicmax化妆品的增长速度预计将比其行业快得多。

The Bottom Line

底线

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Shanghai Chicmax Cosmetic following these results. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

这里最重要的是,分析师上调了每股收益预期,这表明在这些业绩公布之后,对上海Chicmax Cosmetic的乐观情绪明显增强。令人高兴的是,他们还上调了收入预期,并预测其增长速度将超过整个行业。我们注意到目标股价已上调,这表明分析师认为该业务的内在价值可能会随着时间的推移而提高。

With that in mind, we wouldn't be too quick to come to a conclusion on Shanghai Chicmax Cosmetic. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Shanghai Chicmax Cosmetic analysts - going out to 2025, and you can see them free on our platform here.

考虑到这一点,我们不会很快就上海Chicmax化妆品得出结论。长期盈利能力比明年的利润重要得多。根据多位上海Chicmax Cosmetic分析师的估计,到2025年,你可以在我们的平台上免费查看。

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Shanghai Chicmax Cosmetic that you should be aware of.

别忘了可能仍然存在风险。例如,我们已经确定了上海Chicmax化妆品的一个警告信号,你应该注意。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发